Cargando…
Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies
The feasibility of combining cladribine with cyclophosphamide and prednisone in the management of indolent lymphoid malignancies was determined. Nineteen patients [nine chronic lymphocytic leukaemia (CLL), seven non-Hodgkin's lymphoma (NHL) and three macroglobulinaemia (M))] received cladribine...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1999
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362247/ https://www.ncbi.nlm.nih.gov/pubmed/10098762 http://dx.doi.org/10.1038/sj.bjc.6690195 |
_version_ | 1782153410539159552 |
---|---|
author | Laurencet, F M Zulian, G B Guetty-Alberto, M Iten, P A Betticher, D C Alberto, P |
author_facet | Laurencet, F M Zulian, G B Guetty-Alberto, M Iten, P A Betticher, D C Alberto, P |
author_sort | Laurencet, F M |
collection | PubMed |
description | The feasibility of combining cladribine with cyclophosphamide and prednisone in the management of indolent lymphoid malignancies was determined. Nineteen patients [nine chronic lymphocytic leukaemia (CLL), seven non-Hodgkin's lymphoma (NHL) and three macroglobulinaemia (M))] received cladribine 0.1 mg kg(−1) per day as a subcutaneous bolus injection on days 1–3 (up to 5 injections) with intravenous cyclophosphamide 500 mg m(−2) on day 1 and oral prednisone 40 mg m(−2) on days 1–5 at 4-weekly intervals up to a maximum of six courses. A total of 80 courses were given. Overall response rate was 88%, with four patients achieving a complete clinical and haematological response and 12 achieving a partial response. Neutropenia WHO grade 4 in two patients and WHO grade 3 infection in one patient were the limiting toxicities on treatment. During the follow-up, WHO grade ≥3 haematological complications occurred in five patients and WHO grade ≥3 non-haematological complications in five patients. There were no treatment-related deaths. This study demonstrates the feasibility of the cladribine/cyclophosphamide/prednisone (CCP) combination that appears highly active and safe in the management of indolent lymphoid malignancies. © 1999 Cancer Research Campaign |
format | Text |
id | pubmed-2362247 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1999 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23622472009-09-10 Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies Laurencet, F M Zulian, G B Guetty-Alberto, M Iten, P A Betticher, D C Alberto, P Br J Cancer Regular Article The feasibility of combining cladribine with cyclophosphamide and prednisone in the management of indolent lymphoid malignancies was determined. Nineteen patients [nine chronic lymphocytic leukaemia (CLL), seven non-Hodgkin's lymphoma (NHL) and three macroglobulinaemia (M))] received cladribine 0.1 mg kg(−1) per day as a subcutaneous bolus injection on days 1–3 (up to 5 injections) with intravenous cyclophosphamide 500 mg m(−2) on day 1 and oral prednisone 40 mg m(−2) on days 1–5 at 4-weekly intervals up to a maximum of six courses. A total of 80 courses were given. Overall response rate was 88%, with four patients achieving a complete clinical and haematological response and 12 achieving a partial response. Neutropenia WHO grade 4 in two patients and WHO grade 3 infection in one patient were the limiting toxicities on treatment. During the follow-up, WHO grade ≥3 haematological complications occurred in five patients and WHO grade ≥3 non-haematological complications in five patients. There were no treatment-related deaths. This study demonstrates the feasibility of the cladribine/cyclophosphamide/prednisone (CCP) combination that appears highly active and safe in the management of indolent lymphoid malignancies. © 1999 Cancer Research Campaign Nature Publishing Group 1999-03 /pmc/articles/PMC2362247/ /pubmed/10098762 http://dx.doi.org/10.1038/sj.bjc.6690195 Text en Copyright © 1999 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Regular Article Laurencet, F M Zulian, G B Guetty-Alberto, M Iten, P A Betticher, D C Alberto, P Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies |
title | Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies |
title_full | Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies |
title_fullStr | Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies |
title_full_unstemmed | Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies |
title_short | Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies |
title_sort | cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies |
topic | Regular Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362247/ https://www.ncbi.nlm.nih.gov/pubmed/10098762 http://dx.doi.org/10.1038/sj.bjc.6690195 |
work_keys_str_mv | AT laurencetfm cladribinewithcyclophosphamideandprednisoneinthemanagementoflowgradelymphoproliferativemalignancies AT zuliangb cladribinewithcyclophosphamideandprednisoneinthemanagementoflowgradelymphoproliferativemalignancies AT guettyalbertom cladribinewithcyclophosphamideandprednisoneinthemanagementoflowgradelymphoproliferativemalignancies AT itenpa cladribinewithcyclophosphamideandprednisoneinthemanagementoflowgradelymphoproliferativemalignancies AT betticherdc cladribinewithcyclophosphamideandprednisoneinthemanagementoflowgradelymphoproliferativemalignancies AT albertop cladribinewithcyclophosphamideandprednisoneinthemanagementoflowgradelymphoproliferativemalignancies |